Occupational and environmental thoracic malignancies

被引:33
作者
Gottschall, EB [1 ]
机构
[1] Natl Jewish Med & Res Ctr, Dept Med, Div Environm & Occupat Hlth Sci, Denver, CO 80206 USA
关键词
lung cancer; mesothelioma; occupational disease; arsenic; asbestos; beryllium; bis (chloromethyl) ether; cadmium; chromium; mustard gas; nickel; radon; silica;
D O I
10.1097/00005382-200207000-00003
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Lung cancer is the most common thoracic malignancy caused by exposures at work and in the environment. The most unique thoracic malignancy is mesothelioma, because it is relatively rare and one of only a few neoplasms for which one specific inciting agent-asbestos-has been identified. Based on epidemiologic studies, approximately 15% of lung cancers in men and 5% of lung cancers in women are caused by occupational exposures. The International Agency for Research on Cancer has devised a rating system by which, based on animal and human data, they assign an agent, mixture, or exposure circumstance to one of five categories, ranging from group 1 (agent is carcinogenic to humans) to group 4 (agent is probably not carcinogenic to humans). Group 1 pulmonary carcinogens reviewed in this article include arsenic, asbestos, beryllium, bis (chloromethyl) ether, cadmium, chromium (IV), mustard gas, nickel, radon, and silica. The clinical presentation and pathology of lung cancers and mesothelioma caused by such exposures do not differ from those of cancers caused by other factors. The key to the recognition of a thoracic malignancy caused by workplace or environmental exposures is clinical suspicion and consideration of all causes for the disease present. Recognition of an exposure-related case of lung cancer or mesothelioma can aid in the identification of excess risk for a whole workforce or community and can lead to actions to reduce exposure, thus preventing future cases. In addition, such recognition allows the individuals struck by devastating illness to exercise their legal rights to compensation if so desired.
引用
收藏
页码:189 / 197
页数:9
相关论文
共 97 条
[1]  
ADAMS VI, 1986, CANCER, V58, P1540, DOI 10.1002/1097-0142(19861001)58:7<1540::AID-CNCR2820580727>3.0.CO
[2]  
2-5
[3]  
*AM CANC SOC, 2001, CANC FACTS FIG
[4]   Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography [J].
Bénard, F ;
Sterman, D ;
Smith, RJ ;
Kaiser, LR ;
Albelda, SM ;
Alavi, A .
CHEST, 1998, 114 (03) :713-722
[5]  
Boylan A M, 2000, Curr Opin Pulm Med, V6, P157, DOI 10.1097/00063198-200003000-00013
[6]   Predicted number of lung cancer cases in Germany among former uranium miners of the Wismut [J].
BruskeHohlfeld, I ;
Mohner, M ;
Wichmann, HE .
HEALTH PHYSICS, 1997, 72 (01) :3-9
[7]   New combinations in the treatment of lung cancer - A time for optimism [J].
Bunn, PA ;
Kelly, K .
CHEST, 2000, 117 (04) :138S-143S
[8]   18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study [J].
Carretta, A ;
Landoni, C ;
Melloni, G ;
Ceresoli, GL ;
Compierchio, A ;
Fazio, F ;
Zannini, P .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2000, 17 (04) :377-382
[9]  
Case RAM, 1955, BRIT J PREV SOC MED, V9, P62
[10]  
Checkoway H, 2000, AM J IND MED, V37, P252, DOI 10.1002/(SICI)1097-0274(200003)37:3<252::AID-AJIM2>3.0.CO